We have read with interest the commentary by Siemers et al.  regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A., Perez, K. A., McLean, C. A., Villemagne, V. L., Parker, M. W., Barnham, K. J., & Miles, L. A. (2014). Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica, 128(4), 611-4. https://doi.org/10.1007/s00401-014-1333-8